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Abstract 
As the resistance of Staphylococcus aureus to antibiotics represents a major threat to global health, anti-infectives with novel 
mechanisms must be developed. Novel compounds were generated as potential phenylalanine tRNA synthetase (PheRS) 
inhibitors based on the published homology model of S. aureus PheRS to aid the design process using Molecular Operating 
Environment (MOE) software. PheRS was selected as it is structurally unique enzyme among the aminoacyl-tRNA syntheases 
(aaRS), it is considerably different from human cytosolic and human mitochondrial aaRS and it is essential and conserved 
across bacterial species. The designed compounds were synthesized according to different clear schemes. The compounds were 
confirmed by 1H NMR, 13C NMR, HRMS and/or microanalysis, and they were microbiologically evaluated. 
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Introduction 
Staphylococcus aureus (S. aureus) commonly colonizes human skin and mucosa without causing any infections. 
However, if there is an opportunity for the bacteria to enter the body, through a broken skin or a medical procedure, 
they can cause illnesses which range from mild to life-threatening infections. As they include skin and wound 
infections, infected eczema, abscesses or joint infections, infections of the heart valves (endocarditis), pneumonia 
and bacteraemia (blood stream infection). These severe infections acquired either in health-care facilities or in the 
community [1]. Certain strains of S. aureus developed resistance known as methicillin resistant Staphylococcus 
aureus (MRSA). At present, less than 90% of S. aureus strains are resistant to most penicillin derivatives [2] and 
ordinary antimicrobial agents like drugs from the family of aminoglycosides, macrolides, chloramphenicols, 
tetracyclines and fluoroquinolones so known as multidrug resistant Staphylococcus aureus [3]. 
Increased resistance of MRSA to anti-infective drugs is a threat to global health; so anti-infectives with novel 
mechanisms must be developed. Our potential target in the drug development for the treatment of MRSA infections 
is phenylalanine tRNA synthetase which is considered as the most complex and large enzyme of aminoacyl-tRNA 
synthetases (aaRSs).  
Aminoacyl-tRNA synthetases (aaRSs) (also known as aminoacyl-tRNA ligases) are essential enzymes for protein 
biosynthesis , playing a crucial role in the genetic code translation [4,5]. AaRSs catalyze the attachment of an amino 
acid to its cognate tRNA molecule in a two-step reaction. Firstly, cognate amino acids react with ATP forming 
aminoacyl-adenylate, through a covalent linkage between the 5′-phosphate group of ATP and the carboxyl end of 
the amino acid. Secondly, the activated forms of the amino acids are subsequently attached to 2′-OH or 3′-OH of 
the evolutionarily invariant 3′-adenosine terminus of the cognate tRNA molecule by esterification. The resulting 
aminoacyl-tRNA acts as a substrate for protein biosynthesis which occurs on ribosomes [4]. The aaRSs are 
categorized into two classes according to the structural features of the enzymes. Class I enzymes contain a 
Rossman fold in the catalytic core and two conserved motifs, called HIGH and KMSKS. Class II enzymes have 
an antiparallel β-sheet with three conserved motifs in the catalytic centre. To date only one drug, mupirocin, which 
inhibits a specific type of aaRS (IleRS), has been licensed as a topical antibiotic for the treatment of methicillin-
resistant Staphylococcus aureus (MRSA) [6]. 
Phenylalanine tRNA synthetase (PheRS) is a unique enzyme of the aaRS family, as it is an (αβ)2 heterotetrameric 
enzyme composed of two small alpha subunits and two larger beta subunits. According to the structure, PheRS is 
classified as a class II aaRS as its catalytic domain is built around antiparallel β-sheet but functionally it resembles 
class I because it aminoacylates the 2′ OH of the terminal ribose of tRNA where class II aminoacylate the 3′ OH 
[7,8] .The natural substrate (phenylalanyl-adenylate) was considered as a template for the design of novel potential 
compounds against S. aureus PheRS (Figure 1). 
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Figure 1: Structures of the natural substrate phenylalanyl-adenylate.  
Experimental 
Chemistry 
All employed reagents and solvents were of general purpose or analytical grade and purchase from Fluka, Acros, 
Alfa-Aeser chemicals and Sigma-Aldrich Chemical Company. Solvents were dried over molecular sieves (4 Å). 
Flash column chromatography was performed with silica gel 60 (Merck 40–60 nm, 230–400 mesh) and Thin layer 
chromatography (TLC) was performed on precoated silica gel plates (Merck Kiesegel 60 F254) with visualization 
by UV light (254 nm) and/or vanillin stains. Melting points were determined using Gallenkamp as an electro-
thermal instrument and they are uncorrected. 1H and 13C-NMR spectra were recorded on a Bruker Advance 
DPX500 spectrometer operating at 500 MHz and 125 MHz, respectively. Accurate mass spectroscopic analysis 
was performed at the EPSRC National Mass Spectrometry Centre (Swansea, UK) and at Medac Ltd., Chobham 
Business Centre, Surrey, UK. Elemental analysis was performed at Medac Ltd., Chobham Business Centre, 
Chertsey Road, Surrey, UK. 
General method for the synthesis of methyl 3-(1H-benzimidazol-1-yl)propanoate (4a) and methyl 3-(1H-
indol-1-yl)propanoate (4b) [9] 
To a stirred solution of methylacrylate (3) (3 eq.) and DBU (1 eq.) in acetonitrile (1.2 mL/mmol) benzimidazole 
(1) or indole (2) (2 eq.) was added. The reaction mixture stirred at room temperature for 6 h in case of 
benzimidazole and heated at 50 ºC for 6 h in case of indole. The solvent was evaporated under reduced pressure.  
Methyl 3-(1H-benzimidazol-1-yl)propanoate (4a) (C11H12N2O2, M.wt 204.23) 
The product was purified by flash column chromatography using dichloromethane: methanol, the product was 
collected at 98 : 2 % v/v. Yield: 8.56 g (99 %) as a yellow oil. 
TLC: 10 % methanol in dichloromethane, Rf = 0.61 
1H NMR (CDCl3) δ: 8.03 (s, 1H, CH-imidazole), 7.83 (t, J = 7.4 Hz, 1H, Ar), 7.42 (t, J = 7.6 Hz, 1H, Ar), 7.32 
(m, 2H, CH-Ar), 4.52 (t, J = 6.5 Hz, 2H, CH2), 3.67 (s, 3H, CH3), 2.89 (t, J = 6.3 Hz, 2H, CH2). 
13C NMR (CDCl3) δ: 171.04 (C=O), 143.51 (C), 143.27 (CH-imidazole), 133.30 (C), 123.27 (CH-Ar), 122.41 
(CH-Ar), 120.44 (CH-Ar), 109.34 (CH-Ar), 52.13 (CH3), 40.38 (CH2), 34.17 (CH2). 
Methyl 3-(1H-indol-1-yl)propanoate (4b) (C12H13NO, M.wt 203.24) 
The product was purified by flash column chromatography using n-hexane: ethylacetate, the product was collected 
at 90 : 10 % v/v. Yield: 6.94 g (99.9 %) as a yellow oil. 
TLC: hexane: ethyl acetate, 6: 1, v/v, Rf = 0.44 
1H NMR (CDCl3) δ: 7.85 (d, J = 7.9 Hz, 1H, Ar), 7.50 (d, J = 8.2 Hz, 1H, Ar), 7.44 (t, J = 7.1 Hz, 1H, Ar), 7.37 
(t, J = 7.5 Hz, 1H, Ar), 7.27 (d, J = 3.2 Hz, 1H, Ar), 6.70 (d, J = 3.1 Hz, 1H, Ar), 4.52 (t, J = 6.9 Hz, 2H, CH2), 
3.79 (s, 3H, CH3), 2.90 (t, J = 6.9 Hz, 2H, CH2). 
13C NMR (CDCl3) δ: 171.78 (C=O), 135.87 (C), 128.95 (C), 128.13 (CH-Ar), 121.83 (CH-Ar), 121.25 (CH-Ar), 
119.72 (CH-Ar), 109.34 (CH-Ar), 101.78 (CH-Ar), 51.96 (CH3), 41.88 (CH2), 34.83 (CH2). 
General method for the synthesis of 3-(1H-Benzimidazol-1-yl)propane hydrazide [10,11] (5a) and 3-(1H-Indol-
1-yl)propane hydrazide [12] (5b) 
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To a stirred solution of methyl 3-(1H-benzimidazol-1-yl)propanoate (4a) or methyl 3-(1H-indol-1-yl)propanoate 
(4b) (1 eq.) in methanol (1 mL/mmol), hydrazine monohydrate (5 eq.) was added. The reaction mixture was stirred 
for 3h at room temperature, then evaporation of the solvent under vacuum and co-evaporation with diethyl ether 
to afford solid product. The product was purified by re-crystallization form aqueous ethanol.  
3-(1H-Benzimidazol-1-yl)propane hydrazide [10,11] (5a) (C10H12N4O, M.wt 204.23) 
Yield: 4.2 g (82 %) as yellowish crystals. [Lit. 10 66 %, Lit. 11 91 % as a white solid]. 
Melting Point (ºC): 116-118 [Lit. 10 264-266 oC],  
TLC: 10 % methanol in dichloromethane, Rf = 0.57 
1H NMR (DMSO-d6) δ: 9.08 (br s, 1H, NH, D2O-exchangeable), 8.13 (s, 1H, CH-imidazole), 7.65 (d, J = 8.0 Hz, 
1H, Ar), 7.60 (d, J = 8.0 Hz, 1H, Ar), 7.26 (t, J = 7.2 Hz, 1H, Ar), 7.20 (t, J = 7.2 Hz, 1H, Ar), 4.48 (t, J = 6.6 Hz, 
2H, CH2), 3.93 (br s, 2H, NH2, D2O-exchangeable), 2.61 (t, J = 6.7 Hz, 2H, CH2). 
13C NMR (DMSO-d6) δ: 169.33 (C=O), 144.50 (CH-imidazole), 143.83 (C), 134.08 (C), 122.73 (CH-Ar), 121.92 
(CH-Ar), 119.85 (CH-Ar), 110.87 (CH-Ar), 44.49 (CH2), 32.12 (CH2). 
3-(1H-Indol-1-yl)propane hydrazide [12] (5b) (C11H13N3O, M.wt 203.25) 
Yield: 3.5 g (85 %) as pale-yellow crystals. 
Melting Point (ºC): 94-96 
TLC: 10 % methanol in dichloromethane, Rf = 0.65 
1H NMR (DMSO-d6) δ: 9.04 (s, 1H, NH, D2O-exchangeable), 7.53 (d, J = 7.9 Hz, 1H, Ar), 7.47 (d, J = 8.3 Hz, 
1H, Ar), 7.29 (t, J = 2.6 Hz, 1H, Ar), 7.14 (t, J = 7.4 Hz, 1H, Ar), 7.02 (t, J = 7.4 Hz, 1H, Ar), 6.41 (d, J = 2.3 Hz, 
1H, Ar), 4.41 (t, J = 6.8 Hz, 2H, CH2), 4.15 (s, 2H, NH2, D2O-exchangeable), 2.54 (t, J = 6.8 Hz, 2H, CH2). 
13C NMR (DMSO-d6) δ: 169.63 (C=O), 135.95 (C), 129.19 (CH-Ar), 128.59 (C), 121.48 (CH-Ar), 121.40 (CH-
Ar), 119.42 (CH-Ar), 110.20 (CH-Ar), 101.78 (CH-Ar), 41.84 (CH2), 34.78 (CH2). 
Synthesis of 2-(3-(1H-benzimidazol-1-yl)propanoyl)hydrazine-1-carbothioamide (6a) and 2-(3-(1H-indol-1-
yl)propanoyl)hydrazine-1-carbothioamide (6b) 
A solution of potassium thiocyanate (15.13 mmol) in the least amount of distilled water (2 mL), HCl (1.5 mL) was 
added dropwise, followed by slow addition of a methanolic solution of 3-(substituted)propane hydrazide (5a, b) 
(10.05 mmol). The reaction mixture was stirred at room temperature overnight. The resulting yellow solid was 
collected by filtration and washed several times with water. The product was used in the next step without further 
identification or purification.  
Synthesis of 3-(Substituted)-N′-(4-(4-substituted phenyl)thiazol-2-yl)propane hydrazide (8a-c) 
Equimolar solutions of 2-(3-(1H-benzimidazol-1-yl)propanoyl)hydrazine-1-carbothioamide (6a) or 2-(3-(1H-
indol-1-yl)propanoyl)hydrazine-1-carbothioamide (6b) and appropriate 2-bromo-4′-substituted acetophenone (7a) 
or (7b) in absolute ethanol (20 mL/mmol) was heated under reflux overnight. The solvent was evaporated under 
vacuum. The product was purified by flash column chromatography, followed by preparative TLC for final 
purification. 
3-(1H-benzimidazol-1-yl)-N′-(4-(4-chlorophenyl)thiazol-2-yl)propane hydrazide (8a) (C19H16ClN5OS, M.wt 
397.88) 
Synthesized using 2-bromo-4′-chloroacetophenone (7a) (0.195 g, 0.835 mmol). The product was purified by flash 
column chromatography using dichloromethane: methanol, the product was collected at 93 : 7 % v/v , followed 
by re-crystallization from ethanol then preparative TLC for final purification using 90 % dichloromethane : 10 % 
methanol. Yield: 125 mg (38 %) as a brown solid. 
TLC: 10 % methanol in dichloromethane, Rf = 0.75 
1H NMR (DMSO-d6) δ: 10.28 (s, 1H, NH, D2O-exchangeable), 9.50 (s, 1H, NH, D2O-exchangeable), 8.15 (s, 1H, 
CH-imidazole), 7.82 (d, J = 8.2 Hz, 2H, Ar), 7.66 (t, J = 9.0 Hz, 2H, Ar), 7.44 (d, J = 8.2 Hz, 2H, Ar), 7.24 (m, 
3H, 2 x Ar and CH-thiazole), 4.56 (t, J = 6.5 Hz, 2H, CH2), 2.80 (t, J = 6.5 Hz, 2H, CH2). 
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13C NMR (DMSO-d6) δ: 172.66 (C=O), 170.26 (C), 149.76 (C), 144.57 (CH-imidazole), 143.93 (C), 134.07 (C), 
133.94 (C), 133.41 (C), 132.33 (2 x CH-Ar), 129.08 (2 x CH-Ar), 121.97 (CH-Ar), 121.87 (CH-Ar), 119.90 (CH-
Ar), 110.92 (CH-Ar), 104.35 (CH-thiazole), 40.59 (CH2), 33.93 (CH2).    
3-(1H-Benzimidazol-1-yl)-N′-(4-(4-cyanophenyl)thiazol-2-yl)propane hydrazide (8b) (C20H16N6OS, M.wt 
388.45) 
Synthesized using 2-bromo-4′-cyanoacetophenone (7b) (0.43 g, 1.89 mmol). The product was purified by flash 
column chromatography using dichloromethane: methanol, the product was collected at 95 : 5 % v/v , followed 
by preparative TLC for final purification using 90 % dichloromethane : 10 % methanol. Yield: 153 mg (21 %) as 
a yellow solid. 
TLC: 10 % methanol in dichloromethane, Rf = 0.55 
1H NMR (DMSO-d6) δ: 10.32 (s, 1H, NH, D2O-exchangeable), 9.60 (s, 1H, NH, D2O-exchangeable), 8.15 (s, 1H, 
CH-imidazole), 7.97 (d, J = 8.4 Hz, 2H, Ar), 7.83 (d, J = 8.4 Hz, 2H, Ar), 7.66 (dd, J = 8.0, 13.3 Hz, 2H, Ar), 7.51 
(s, 1H, CH-thiazole), 7.25 (m, 2H, Ar), 4.55 (t, J = 6.3 Hz, 2H, CH2), 2.81 (t, J = 6.2 Hz, 2H, CH2). 
13C NMR (DMSO-d6) δ: 172.83 (C=O), 170.29 (C), 149.27 (C), 144.57 (CH-imidazole), 143.94 (C), 139.15 (C), 
134.08 (C), 133.10 (2 x CH-Ar), 126.64 (2 x CH-Ar), 121.98 (CH-Ar), 121.87 (CH-Ar), 119.91 (CH-Ar), 119.46 
(CN), 110.92 (CH-Ar), 110.02 (C), 107.40 (CH-thiazole), 40.59 (CH2), 33.92 (CH2).    
N′-(4-(4-Cyanophenyl)thiazol-2-yl)-3-(1H-indol-1-yl)propanehydarzide (8c) (C21H17N5OS, M.wt 387.46) 
Synthesized using 2-bromo-4′-cyanoacetophenone (7b) (0.26 g, 1.14 mmol). The product was purified by flash 
column chromatography using petroleum ether: ethylacetate, the product was collected at 40 : 60 % v/v. Yield: 
172 mg (39 %) as a yellow solid.  
TLC: petroleum ether : ethyl acetate 1: 4, v/v, Rf =  0.66 
1H NMR (DMSO-d6) δ: 10.29 (s, 1H, NH, D2O-exchangeable), 9.59 (s, 1H, NH, D2O-exchangeable), 8.00 (d, J 
= 8.2 Hz, 2H, Ar), 7.85 (d, J = 8.2 Hz, 2H, Ar), 7.57 (d, J = 7.5 Hz, 2H, Ar), 7.52 (s, 1H, CH-thiazole), 7.50 (d, J 
= 7.5 Hz, 2H, Ar), 7.33 (s, 1H, Ar), 7.15 (t, J = 7.2 Hz, 1H, Ar), 7.03 (t, J = 7.2 Hz, 1H, Ar), 6.43 (s, 1H, Ar),  4.47 
(t, J = 6.6 Hz, 2H, CH2), 2.72 (t, J = 6.6 Hz, 2H, CH2). 
13C NMR (DMSO-d6) δ: 172.89 (C=O), 170.57 (C), 149.25 (C), 139.15 (C), 135.95 (C), 133.11 (2 x CH-Ar), 
129.04 (CH-Ar), 128.67 (C), 126.63 (2 x CH-Ar), 121.42 (CH-Ar), 120.90 (CH-Ar), 119.51 (CH-Ar), 119.46 
(CN), 110.22 (CH-Ar), 110.06 (C), 107.41 (CH-thiazole), 101.25 (CH-Ar), 41.31 (CH2), 34.53 (CH2).    
Synthesis of 5-(2-(1H-benzimidazol-1-yl)ethyl)-1,3,4-thiadiazol-2-amine (9) (C11H11N5S, M.wt 245.07) 
Potassium thiocyanate (1.07 g, 11.02 mmol) was dissolved in the least amount of water (2 mL) then hydrochloric 
acid (1 mL) was added dropwise. The aforementioned mixture was added to a methanolic solution of 3-(1H-
benzimidazol-1-yl)propane hydrazide (5a) (1.5 g, 7.34 mmol). The reaction mixture was stirred overnight at room 
temperature, followed by solvent evaporation under vacuum. The resulting solid was added portionwise to H2SO4 
(5 mL) with continuous stirring. The reaction mixture was stirred for 2 h, then slowly poured into crushed ice with 
stirring and neutralized with ammonia solution. The resulting pale brown solid was collected by filtration under 
vacuum. The product was pure enough to proceed to further reaction. Yield: 1.5 g (88 %) as a pale-brown solid. 
Melting Point (ºC): 182-184 
TLC: 10 % methanol in dichloromethane, Rf = 0.37 
1H NMR (DMSO-d6) δ: 8.16 (s, 1H, CH-imidazole), 7.63 (t, J = 7.5 Hz, 2H, Ar), 7.26 (t, J = 7.3 Hz, 1H, Ar), 
7.21 (t, J = 7.5 Hz, 1H, Ar), 7.03 (s, 2H, NH2, D2O-exchangeable), 4.60 (t, J = 6.7 Hz, 2H, CH2), 3.40 (t, J = 6.7 
Hz, 2H, CH2). 
13C NMR (DMSO-d6) δ: 169.15 (C), 154.69 (C), 144.61 (CH-imidazole), 143.89 (C), 134.12 (C), 122.81 (CH-
Ar), 121.99 (CH-Ar), 119.92 (CH-Ar), 110.90 (CH-Ar), 43.68 (CH2), 30.32 (CH2) 
[ESI-HRMS] Calculated mass: 246.0726 [M+H]+, Measured mass: 246.0720 [M+H]+. 
General method for the synthesis of N-(5-(2-(1H-benzimidazol-1-yl)ethyl)-1,3,4-thiadiazol-2-yl)-
substituted benzamide (11a, b) 
To a solution of 5-(2-(1H-benzimidazol-1-yl)ethyl)-1,3,4-thiadiazol-2-amine (9) (1 eq.) in dry dichloromethane 
(10 mL/mmol), triethylamine (10 eq.) was added. The reaction mixture was cooled to 0 ºC, followed by addition 
of 3,5-dimethoxybenzoyl chloride (10a) or 4-fluorobenzoyl chloride (10b) (1.1 eq.) in dry dichloromethane (10 
mL) dropwise over 30 min. Then, the reaction mixture was stirred at room temperature overnight. Solvent was 
- 6 - 
 
evaporated under pressure and the resulting solid was extracted with dichloromethane (50 mL/mmol) and saturated 
aqueous sodium bicarbonate (3 x 25 mL/mmol). The organic layer was dried over anhydrous magnesium sulfate, 
filtered and evaporated under reduced pressure. The product was purified by flash column chromatography using 
gradient elution of dichloromethane: methanol, the product was collected at 96 : 4 % v/v. 
N-(5-(2-(1H-benzimidazol-1-yl)ethyl)-1,3,4-thiadiazol-2-yl)-3,5-dimethoxybenzamide (11a) (C20H19N5O3S, 
M.wt 409.46) 
Yield: 0.15 g (56 %) as a white solid. 
Melting Point (ºC): 200-202 
TLC: 10 % methanol in dichloromethane, Rf = 0.6 
1H NMR (DMSO-d6) δ: 12.95 (s, 1H, NH, D2O-exchangeable), 8.18 (s, 1H, CH-imidazole), 7.66 (t, J = 8.3 Hz, 
2H, Ar), 7.25 (m, 4H, Ar), 6.76 (s, 1H, Ar), 4.72 (t, J = 6.8 Hz, 2H, CH2), 3.82 (s, 6H, 2 x CH3), 3.62 (t, J = 6.8 
Hz, 2H, CH2). 
13C NMR (DMSO-d6) δ: 165.10 (C=O), 161.11 (C), 160.94 (2 x C), 160.17 (C), 144.57 (C), 143.90 (CH-
imidazole), 134.33 (C), 133.83 (C), 129.11 (CH-Ar), 122.84 (CH-Ar), 122.04 (CH-Ar), 119.95 (CH-Ar), 110.91 
(CH-Ar), 106.47 (CH-Ar), 105.79 (CH-Ar), 55.06 (CH3), 43.76 (CH2), 29.94 (CH2). 
[ESI-HRMS] Calculated mass: 410.1281 [M+H]+, Measured mass: 410.1278 [M+H]+. 
N-(5-(2-(1H-benzimidazol-1-yl)ethyl)-1,3,4-thiadiazol-2-yl)-4-fluorobenzamide (11b) (C18H14FN5OS, M.wt 
367.40) 
Yield: 0.4 g (45 %) as a yellow solid. 
Melting Point (ºC): 210-212 
TLC: 10 % methanol in dichloromethane, Rf = 0.8 
1H NMR (DMSO-d6) δ: 13.03 (s, 1H, NH, D2O-exchangeable), 8.17 (t, J = 7.5 Hz, 3H, 2 Ar and CH-imidazole), 
8.01 (d, J = 8.8 Hz, 1H, Ar), 7.66 (d, J = 8.0 Hz, 1H, Ar), 7.27 (m, 4H, Ar), 4.72 (t, J = 6.8 Hz, 2H, CH2), 3.62 (t, 
J = 6.8 Hz, 2H, CH2). 
13C NMR (DMSO-d6) δ: 166.84 (C=O), 166.38 (C), 164.39 (C), 161.07 (C), 143.90 (CH-imidazole), 143.88 (C), 
134.07 (C), 132.61 (CH-Ar), 132.54 (CH-Ar), 128.67 (C), 122.84 (CH-Ar), 122.04 (CH-Ar), 119.94 (CH-Ar), 
116.18 (CH-Ar), 116.00 (CH-Ar), 110.91 (CH-Ar), 43.73 (CH2), 29.96 (CH2). 
[ESI-HRMS] Calculated mass: 368.0976 [M+H]+, Measured mass: 368.0977 [M+H]+. 
General procedures for the synthesis of 5-(3-(1H-Benzimidazol-1-yl)propyl)-4-phenyl-2,4-dihydro-3H-
1,2,4-triazole-3-thione (14) and 5-(3-(6-Amino-9H-purin-9-yl)propyl)-4-phenyl-2,4-dihydro-3H-1,2,4-
triazole-3-thione (15) 
To a suspension of 2-(4-(1H-benzimidazol-1-yl)butanoyl)-N-phenylhydrazine-1-carbothioamide (12) or 2-(4-(6-
amino-9H-purin-9-yl)butanoyl)-N-phenylhydrazine-1-carbothioamide (13) (1 eq.) in ethanol (15 mL/mmol) was 
added 2N aqueous  NaOH (5 mL/mmol) dropwise with continuous stirring. The reaction mixture was stirred at 
room temperature for 5 h. Evaporation of ethanol under reduced pressure. The solution was neutralized by the 
addition of HCl dropwise until the formation of a white precipitate. The precipitate was collected by filtration 
under vacuum.  
5-(3-(1H-Benzimidazol-1-yl)propyl)-4-phenyl-2,4-dihydro-3H-1,2,4-triazole-3-thione (14) (C18H17N5S, 
M.wt 335.43) 
The product was purified by flash column chromatography using dichloromethane: methanol, the product was 
collected at 96 : 4 % v/v. Yield: 0.204 g (72 %) as a white solid. 
Melting Point (ºC): 98-100 
TLC: 10 % methanol in dichloromethane, Rf = 0.52 
1H NMR (DMSO-d6) δ: 13.61 (br s, 1H, NH, D2O-exchangeable), 8.04 (s, 1H, CH-imidazole), 7.92 (d, J = 6.9 
Hz, 1H, Ar), 7.48 (d, J = 6.5 Hz, 3H, Ar), 7.31 (3H, J = 6.7 Hz, Ar), 7.20 (t, J = 3.0 Hz, Ar), 4.30 (t, J = 6.7 Hz, 
2H, CH2), 2.48 (t, J = 6.9 Hz, 2H, CH2), 2.21 (quin., J = 6.9 Hz, 2H, CH2). 
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13C NMR (DMSO-d6) δ: 168.90 (C), 151.07 (C), 142.98 (CH-imidazole), 144.00 (C), 133.47 (C), 133.06 (C), 
130.22 (2 x CH-Ar), 130.01 (2 x CH-Ar), 127.65 (CH-Ar), 123.26 (CH-Ar), 122.50 (CH-Ar), 120.59 (CH-Ar), 
109.44 (CH-Ar), 43.43 (CH2), 25.58 (CH2), 22.79 (CH2). 
[ESI-HRMS] Calculated mass: 336.1277 [M+H]+, Measured mass: 336.1284 [M+H]+. 
5-(3-(6-Amino-9H-purin-9-yl)propyl)-4-phenyl-2,4-dihydro-3H-1,2,4-triazole-3-thione (15) (C16H16N8S, 
M.wt 352.42 ) 
The product was purified by re-crystallization from aqueous ethanol. Yield: 2.3 g (97 %) as white crystals. 
Melting Point (ºC): 280-282 
TLC: 10 % methanol in dichloromethane, Rf = 0.4 
1H NMR (DMSO-d6)δ: 13.73 (s, 1H, NH, D2O-exchangeable), 8.09 (s, 1H, CH-imidazole), 8.03 (s, 1H, CH-
pyrimidine), 7.49 (d, J = 6.5 Hz, 3H, Ar), 7.35 (d, J = 7.6 Hz, 2H, Ar), 7.17 (s, 2H, NH2, D2O-exchangeable), 4.15 
(t, J = 6.6 Hz, 2H, CH2), 2.41 (t, J = 7.3 Hz, 2H, CH2), 2.06 (quin., J = 6.8 Hz, 2H, CH2). 
13C NMR (DMSO-d6) δ: 172.91 (C), 161.15 (C), 157.56 (CH-pyrimidine), 156.48 (C), 154.68 (C), 141.33 (CH-
imidazole), 138.76 (C), 134.60 (2 x CH-Ar), 134.51 (2 x CH-Ar), 133.35 (CH-Ar), 123.94 (C), 47.13 (CH2), 30.68 
(CH2), 27.77 (CH2). 
[ESI-HRMS] Calculated mass: 353.1291 [M+H]+, Measured mass: 353.1291 [M+H]+. 
General procedure for the synthesis of 1-(3-(4-phenyl-5-(substituted thio)-4H-1,2,4-triazol-3-yl)propyl)1H-
benzimidazole (16a,b).  
To a mixture of 5-(3-(1H-benzimidazol-1-yl)propyl)-4-phenyl-2,4-dihydro-3H-1,2,4-triazole-3-thione (14) (1 eq.) 
and anhydrous potassium carbonate (1.5 eq.) in dry DMF (10 mL/0.5 mmol) iodoethane or 1-iodopropane (1 eq.) 
in dry DMF (5 mL/0.5 mmol) was added. The reaction mixture was stirred overnight at room temperature. The 
reaction mixture was concentrated under vacuum and the residue was dissolved in ethyl acetate (100 mL/0.5 mmol) 
and washed with water (3 x 50 mL/0.5 mmol). The organic layer was dried over anhydrous MgSO4 and 
concentrated under vacuum.  
1-(3-(5-(Ethylthio)-4-phenyl-4H-1,2,4-triazol-3-yl)propyl)-1H-benzimidazole (16a) (C20H21N5S, M.wt 
363.48) 
The product was purified by flash column chromatography using gradient elution of dichloromethane: methanol, 
the product was collected at 94 : 6 % v/v. Yield: 0.2 g (84 %) as a yellowish solid. 
Melting Point (ºC): 118-120 
TLC: 10 % methanol in dichloromethane, Rf = 0.6 
1H NMR (CDCl3) δ: 7.85 (s, 1H, CH-imidazole), 7.78 (d, J = 6.9 Hz, 1H, Ar), 7.48: 7.42 (m, 3H, Ar), 7.29 (m, 
3H, Ar), 7.04 (d, J = 7.1 Hz, 1H, Ar), 4.41 (t, J = 6.7 Hz, 2H, CH2), 3.23 (q, J = 7.3 Hz, 2H, CH2), 2.48 (t, J = 6.9 
Hz, 2H, CH2), 2.29 (quin., J = 6.6 Hz, 2H, CH2), 1.41 (t, J = 7.3 Hz, 3H, CH3). 
13C NMR (CDCl3) δ: 154.13 (C), 151.90 (C), 143.86 (C), 143.04 (CH-imidazole), 133.73 (C), 132.90 (C), 130.09 
(2 x CH-Ar), 130.02 (2 x CH-Ar), 126.82 (CH-Ar), 122.93 (CH-Ar), 122.10 (CH-Ar), 120.39 (CH-Ar), 109.68 
(CH-Ar), 43.40 (CH2), 26.88 (CH2), 21.79 (CH2), 14.77 (CH3). 
Microanalysis:  
Theoretical: %C: 66.09, %H: 5.82, %N: 19.26, Found: %C: 65.64, %H: 5.74, %N: 19.09. 
1-(3-(4-Phenyl-5-(propylthio)-4H-1,2,4-triazol-3-yl)propyl)1H-benzimidazole (16b) (C21H23N5S, M.wt: 
377.51) 
The product was purified by flash column chromatography using gradient elution of dichloromethane: methanol, 
the product was collected at 97 : 3 % v/v. Yield: 0.27 g (80 %) as a yellow oil. 
TLC: 10 % methanol in dichloromethane, Rf = 0.6 
1H NMR (CDCl3) δ: 7.86 (s, 1H, CH-imidazole), 7.76 (d, 1H, J = 6.7, Ar), 7.41: 7.47 (m, 3H, Ar), 7.29 (d, J = 
7.6, 1H, Ar), 7.22: 7.26 (m, 3H, Ar), 7.02 (d, J = 7.0, 2H, Ar), 4.38 (t, J = 6.7, 3H, CH2), 3.17 (t, J= 7.3, 3H, CH2), 
2.47 (t, J = 6.7, 3H, CH2), 2.27 (quin., J = 6.6 Hz, 2H, CH2), 1.75 (m, 2H, CH2), 0.98 (t, J = 7.2, 3H, CH3) 
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13C NMR (CDCl3) δ: 154.12 (C), 152.12 (C), 143.69 (C), 143.02 (CH-imidazole), 133.69 (C), 132.88 (C), 130.08 
(2 x CH-Ar), 130.01 (2 x CH-Ar), 126.82 (CH-Ar), 122.96 (CH-Ar), 122.14 (CH-Ar), 120.29 (CH-Ar), 109.72 
(CH-Ar), 43.43 (-CH2), 34.42 (CH2), 26.30 (CH2), 22.75 (CH2), 21.79 (CH2), 13.24 (CH3). 
[ESI-HRMS] Calculated mass: 378.1747 [M+H]+, Measured mass: 378.1749 [M+H]+. 
General procedure for the synthesis of 9-(3-(4-phenyl-5-(substituted thio)-4H-1,2,4-triazol-3-yl)propyl)-9H-
purin-6-amine (17a,b) 
To a mixture of 5-(3-(6-amino-9H-purin-9-yl)propyl)-4-phenyl-2,4-dihydro-3H-1,2,4-triazole-3-thione (15) (1 
eq.) and anhydrous potassium carbonate (1.5 eq.) in dry DMF (10 mL/0.5 mmol) iodoethane or 1-iodopropane (1 
eq.) in dry DMF (5 mL/ 0.5 mmol) was added. The reaction mixture was stirred overnight at room temperature. 
The reaction mixture was concentrated under vacuum and the residue was dissolved in ethyl acetate (100 mL/0.5 
mmol) and washed with water (3 x 50 mL/0.5 mmol). The organic layer was dried over anhydrous MgSO4 and 
concentrated under vacuum. 
9-(3-(5-(Ethylthio)-4-phenyl-4H-1,2,4-triazol-3-yl)propyl)-9H-purin-6-amine (17a) (C18H20N8S, M.wt 
380.47 ) 
The product was purified by flash column chromatography using gradient elution of dichloromethane: methanol, 
the product was collected at 92 : 8 % v/v. Yield: 0.6 g (86 %) as yellow crystals.  
Melting Point (ºC): 180-182oC 
TLC: 10% methanol in dichloromethane, Rf = 0.3 
1H NMR (DMSO-d6) δ: 8.09 (s, 1H, CH-pyrimidine), 8.04 (s, 1H, CH-imidazole), 7.51 (m, 3H, Ar), 7.35 (m, 2H, 
Ar), 7.18 (s, 2H, NH2), 4.17 (t, J = 6.8, 2H, CH2), 3.04 (q, J = 7.4 Hz, 2H, CH2), 2.52 (masked by DMSO peak, 
CH2), 2.12 (quin., J = 6.7 Hz, 2H, CH2), 1.26 (t, J = 7.4, 3H, CH3). 
13C NMR (DMSO-d6) δ: 156.40 (C), 154.97 (C), 152.78 (CH-Ar), 150.25 (C), 149.93 (C), 141.20 (CH-Ar), 
133.46 (C), 130.28 (2 x CH-Ar), 130.22 (2 x CH-Ar),127.65 (CH-Ar), 119.23 (C), 42.62 (CH2), 27.03 (CH2), 
26.85 (CH2), 22.36 (CH2), 15.28 (CH3). 
Microanalysis:  
Theoretical: %C: 56.82, %H: 5.30, %N: 29.44, Found: %C: 56.33, %H: 5.22, %N: 28.99. 
9-(3-(4-Phenyl-5-(propylthio)-4H-1,2,4-triazol-3-yl)propyl)-9H-purin-6-amine (17b) (C19H22N8S, M.wt 
394.50 ) 
The product was purified by flash column chromatography using gradient elution of dichloromethane: methanol, 
the product was collected at 94 : 6 % v/v. Yield: 0.64 g (88 %) as white crystals. 
Melting Point (ºC): 174-178 
TLC: 10 % methanol in dichloromethane, Rf = 0.58 
1H NMR (DMSO-d6) δ: 8.10 (s, 1H, CH-pyrimidine), 8.05 (s, 1H, CH-imidazole), 7.51 (m, 3H, Ar), 7.35 (m, 2H, 
Ar), 7.20 (s, 2H, NH2), 4.17 (t, J = 6.7, 2H, CH2), 3.02 (t, J = 6.9, 2H, CH2), 2.52 (t, J = 7.6, 2H, CH2), 2.12 (quin., 
J = 6.6 Hz, 2H, CH2), 1.62 (m, 2H, CH2), 0.90 (t, J = 7.3, 3H, CH3). 
13C NMR (DMSO-d6) δ: 156.38 (C), 154.96 (C), 152.76 (CH-Ar), 150.38 (C), 149.92 (C), 141.21 (CH-Ar), 
133.47 (C), 130.28 (2 x CH-Ar), 130.22 (2 x CH-Ar), 127.65 (CH-Ar), 119.22 (C), 42.62 (CH2), 34.54 (CH2), 
26.85 (CH2), 22.79 (CH2), 22.36 (CH2), 13.35 (CH3). 
Microanalysis:  
Theoretical: %C: 57.85, %H: 5.62, %N: 28.40, Found: %C: 57.46, %H: 5.58, %N: 28.29. 
Molecular modeling 
Docking studies were performed using MOE software [13] utilizing the homology model for S. aureus phenylalanine 
tRNA synthetase enzyme having phenylalanyl adenylate as a ligand [14]. Ligands were built using MOE and then 
the energy was minimized for each ligand, creating a ligand database.  All minimizations were performed with 
MOE to a RMSD gradient of 0.01 Kcal/mol/Å with MMFF94 forcefield, and partial charges were automatically 
calculated. The ligands were docked using the MOE default setting: Placement: Triangular Matcher, Rescoring 1: 
London G, 30 poses were constructed for each compound and the best scoring model-ligand complexes were 
selected. The consequent ligand interactions within the constructed model were visualized using the MOE ligand 
interaction simulation.  
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Microbiological evaluation 
The synthesized compounds were evaluated for MIC against S. aureus SH1000 sensitive strain according to CSLI 
guidelines 2012 [15].  
Moreover, compounds 11b, 16a, 17a and 17b were evaluated for their antimicrobial activity alongside comparator 
agent ampicillin (Amp) against a variety of clinically important pathogens. Isolates tested included clinical and 
NCTC/ATCC control organisms; S. aureus (including methicillin, tetracycline, erythromycin/clindamycin and 
vancomycin resistance), Klebsiella pneumoniae (including 3rd generation cephalosporin and carbapenem 
resistance), Proteus mirabilis, Pseudomonas aeruginosa, Salmonella enteritidis, Acinetobacter baumannii, 
Enterococcus faecalis and faecium (including vancomycin resistance) and E. coli. Minimum Inhibitory 
Concentrations (MICs) were determined using microbroth dilution, the “gold standard”, international standard ISO 
10776-1[16].  
P. aeruginosa PheRS and S. pneumonia PheRS enzymes assay 
The inhibitory activity (IC50) of the final compounds was determined using the tRNA aminoacylation assay 
adapted to a scintillation proximity assay (SPA) [17]. Test compounds were dissolved in 100% DMSO to a 
concentration of 3.3 mM. To determine IC50 values the test compounds (2 μl) were serially diluted across 10 wells 
on the assay plates resulting in final assay concentrations ranging from 200 μM to 0.4 μM. Briefly, the compounds 
were equilibrated by the addition of 33 μL of the protein/substrate mix: 50 mM Tris-HCl (pH 7.5), 8 mM MgCl2, 
1.25 mM ATP, 1 mM spermine, 1 mM DTT, 100 μM [3H]Phe (75 cpm/pmol), and 0.08 μM P. aeruginosa PheRS 
or 0.2 μM S. pneumonia PheRS. Control reactions contained only DMSO with no compound. This mixture was 
incubated at ambient temperature for 15 min and then reactions were started by the addition of 15 μl E. coli tRNA 
(80 μM total tRNA or 2 μM tRNAPhe), followed by incubation for 1 h at 37 °C. Reactions were stopped by the 
addition of 5 µl of 0.5 M EDTA. 400 μg of yttrium silicate (Ysi) poly-L-lysine coated SPA beads (Perkin-Elmer) 
in 150 μl of 300 mM citric acid were added and allowed to incubate at room temperature for 1 h. The plates were 
analyzed using a 1450 Microbeta (Jet) liquid scintillation/luminescent counter (Wallac). The curve fits and IC50 
values were determined using the Sigmoidal Dose-Response Model in XLfit 5.3 (IDBS).  
Results and discussion 
Chemistry 
The sequence of the reactions followed in the preparation of the designed compounds is summarized in 
Schemes 1-3.  
 
Scheme 1: Reagents and conditions: (i) DBU, CH3CN, rt or 50 ºC, 6h (ii) hydrazine monohydrate, MeOH, rt, 3 h 
(iii) KSCN, Conc. HCl, MeOH, rt, overnight (iv) EtOH, reflux, overnight. 
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The synthesis of methyl esters (4a) and (4b) were carried out via an aza-Michael addition reaction. Hydrazinolysis 
of the methyl ester compounds (4a,b) produced hydrazides [18] (5a,b) which were confirmed by the disappearance 
of the CH3 peak from both 1H NMR and 13C NMR spectra. 1H NMR spectrum showed two singlet signals at ~ 9.0 
ppm and ~ 4.0 ppm for the protons of NH and NH2 groups, respectively. Several attempts were investigated to 
convert (4a, b) directly to (6a, b) without the hydrazinolysis step according to literature [19,20]. These trials involved 
refluxing the ester compounds 4a, b with thiosemicarbazide in the presence of either acetone, EtOH with few 
drops of AcOH or EtOH with a few drops of dimethylsulfoxide (DMSO). However, all attempts were unsuccessful, 
based on 1H NMR analysis. Therefore, an alternative pathway was taken, based on the reaction of the hydrazides 
(5a, b) with KSCN through nucleophilic addition reaction [21]. Compounds 8a-c having 1,3-thiazole ring were 
achieved by the reaction of 6a or 6b and appropriate 2-bromo-4′-substituted acetophenone (7a) or (7b) in EtOH 
under reflux overnight [22,23]. After column chromatography purification, it was found that 1H NMR showed a few 
impurities. So, compound 8a was further purified by re-crystallization. However, the compound changed color 
during the heating of the re-crystallization process, and TLC showed several spots, indicating that the compound 
is heat sensitive. Preparative TLC was utilized for final purification of compound 8a. For compounds 8b and 8c, 
fast column chromatography was done to avoid any decomposition in the desired compounds, then purified with 
preparative TLC. 1H and 13C NMR confirmed the structures with the singlet CH-thiazole peak at approximately 
7.5 ppm in the 1H NMR. The yields of this reaction were very low. Mass spectroscopy or microanalysis was not 
conducted for the structures of the prepared compounds owing to the instability (Scheme 1). 
 
Scheme 2:  Reagents and conditions: (i) KSCN, HCl, MeOH, rt, overnight (ii) Conc. H2SO4, 2h, aqueous NH3 (iii) 
CH2Cl2, Et3N, 0 ºC – rt, overnight. 
5-(2-(1H-benzimidazol-1-yl)ethyl)-1,3,4-thiadiazol-2-amine (9) was achieved by the reaction of a methanolic 
solution of 3-(1H-benzimidazol-1-yl)propane hydrazide (5a) with KSCN in acidic solution through a nucleophilic 
addition reaction [24,25]. The acidic condition afforded the cyclization of the 1,3,4-thiadiazole ring. 1H NMR 
spectrum showed downfield singlet signal at 7.03 ppm corresponding to the two protons of the primary amino 
group and more carbon atom at 154.69 ppm appeared in 13C NMR spectrum. The synthesis of 11a, b was achieved 
through the nucleophilic substitution reaction of 9 with benzoyl chloride derivatives (10a) or (10b) in 
CH2Cl2/Et3N. The low product yield was presumably owing to the reduced nucleophilicity of the primary amino 
group (Scheme 2). 
 
Scheme 3: Reagents and conditions: (i) (a) 2N NaOH, 5 h, rt, (b) Conc. HCl (ii) Alkyl halide, anhyd. K2CO3, DMF, 
rt, overnight. 
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Thiosemicarbazide (12, 13) cyclization in alkaline medium resulted in the formation of 1,2,4-triazoles (14, 15). 
This is because N-4, in alkaline medium, is more nucleophilic than the sulfur of the thiocarbonyl group and oxygen 
of carbonyl group producing 1,2,4-trizoles [26-28]. Treatment of 14 or 15 with potassium carbonate as a base and an 
appropriate alkyl halide gave the desired thioethers (16 and 17) in very good yields (Scheme 3).  
Molecular modeling evaluation 
These series were developed to include either adenine or a biarylmimic (benzimidazole or indole) to represent the 
adenyl moiety of phenylalanyl adenylate (Table 1). The ‘adenyl’ portion was linked, through a 3-5 atom linker 
that spans the hydrophobic channel, to a heterocyclic 5-membered ring having either thiol or nitrogen or both to 
make H-bonds with the key binding amino acid residues (His172, Ser174, Gln214 and/or Glu216), and finally the 
remainder of the compound, which may be aliphatic or aromatic, to fill the large hydrophobic pocket and may 
contributed with H-bond interactions. 
Table 1: 3D and 2D models of binding interactions of phenylalanyl-adenylate in S. aureus PheRS active site [14] 
3D structure 2D ligand interactions 
 
 
The compounds were investigated through docking studies. The thiol group, amino group and/or carbonyl group 
for compounds 8a - c showed interactions with the following binding residues in the active site: Ser174, Gln214 
and Gly288. The amide group in compounds 11a and 11b interacted with Ser174 and Ala311 and the thiol group 
of 1,3,4-thiadiazolyl moiety interacted with His172. As observed for compounds 16a, 17a and 17b, the thiol group 
formed a H-bond with acidic Glu216 and for compound 16b, Gln214 formed a H-bond with the 1,2,4-triazole 
moiety (Table 2). 
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Microbiological evaluation 
Compounds 8a-c were not subjected to microbiological evaluation because of their instability. Nevertheless, none 
of the tested compounds showed inhibitory activity (MIC ≥ 128 µg/mL) against S. aureus SH1000 sensitive strains. 
The synthesized compounds were microbiologically tested for P. aeruginosa PheRS and S. pneumonia PheRS 
inhibition through aminoacylation assay due to the availability of these enzymes and their high degree of similarity 
with S. aureus PheRS. Analysis of the synthesized series resulted in only compound 34a (IC50 199 M) exhibiting 
moderate inhibitory activity (Table 3). 
Table 3: MIC (g/mL) values against S. aureus sensitive SH1000 strain and IC50 data against S. pneumonia PheRS and 
P. aeruginosa PheRS (M) 
 MIC (g/mL) 






11a >128 345 742 
11b >128 685 907 
16a >128 561 343 
16b >128 390 375 
17a >128 619 199 
17b >128 686 294 
 
Moreover, compounds (11b, 16a, 17a and 17b) showed no inhibitory activity (MIC ≥ 128 μg/mL) against the 
tested bacteria. However, moderate inhibitory activity (32-64 μg/mL) was observed with 11b and 17a against E. 
faecalis sensitive and vanA and vanB resistant strains (Table 4). 
Table 4: Broad microbiological evaluation of 11b, 16a, 17a and 17b (MIC (g/mL) determination) 
Organism Amp 11b 16a 17a 17b 
S. aureus ATCC 
29213 sensitive 
4 >128 >128 >128 >128 
S. aureus NCTC 
12493 mecA resistant 
>128 128 >128 128 >128 
K. pneumoniae 21856 
sensitive 
>128 >128 >128 >128 >128 
P. mirabilis NCTC 
10975 sensitive 
>128 >128 >128 >128 >128 
P. aeruginosa ATCC 
27853 sensitive 
>128 >128 >128 >128 >128 
S.enteritidis8204 
sensitive 
8 >128 >128 >128 >128 
A.baumannii572 
sensitive 
>128 >128 >128 >128 >128 
B.cepacia NCTC 
10661 sensitive 
>128 >128 >128 >128 >128 
E. faecalisATCC 
29212 sensitive 
2 64 >128 >128 >128 
E. faecalis NCTC 
12201 vanA resistant 
16 32 >128 64 >128 
E. faecalis ATCC 
51299 vanB resistant 
8 64 >128 64 >128 
E. faecium 16568 
sensitive 
4 - >128 - >128 
E. coli ATCC 25922 
sensitive 
8 >128 >128 >128 >128 
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Conclusion 
In summary, three novel series were designed and synthesized depending on the natural substrate, phenylalanyl-
adenylate. All designed compounds make H-bonds with the key amino acid residues allowing the orientation of 
the compounds in the adenylate and amino acid binding sites. As the compounds in thiazole series are unstable, 
the future work should be optimization for the structure for further investigation of compound stability and yield. 
Analysis of the thiadiazole and triazole series resulted in only compound 17a (IC50 199 M) exhibiting moderate 
inhibitory activity against P. aeruginosa PheRS. Compounds 11b and 17a showed moderate inhibitory activity 
(32-64 μg/mL) against E. faecalis sensitive and vanA and vanB resistant strains. 
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 الملخص العربى
تصميم و تشييد وتقييم مركبات جديدة تعمل كمثبطات لمخلق فينيل الانين الحمض الريبى النووى النقال لعلاج بكتيريا 
 ستافيلوكوكس أوريس
، محمد  ب، السيد محمد لاشين ب ابراهيم مجاهد ، سامى  ه، أريا جوبتا  د، جينيفير ريتشاردز  ج، كاسي هوجيس  *أ. بسمر سعيد البرماوى
 . بأ، كلير سيمونس  ج، جاميز بولرد د ، ماندى ووتتن  ه، أليكس اونيل ب الحسينى الصادق 
 كلية الصيدلة و العلوم الصيدلية، جامعة كارديف، كارديف، المملكة المتحدةأ 
 ، جمهورية مص العربية91544قسم الكيمياء الدوائية، كلية الصيدلة، جامعة الزقازبق، ص.ب:  ب
 قسم الكيمياء، جامعة تيكساس، ادينبرج، الولايات المتحدة الأمريكية ج
 وحدة مضادات البكتيريا المتخصصة، مستشفى جامعة ويلز التعليمية، كارديف، المملكة المتحدةد 
 يوية، جامعة ليدز، ليدز، المملكة المتحدةكلية العلوم الح ه 
ي تتشكل زيادة مقاومة الميكروبات للعقاقير المضادة للعدوى تهديدا ًللصحة على الصعيد العالمي، و من ثم يجب وضع آليات جديدة للأدوية ال
و  يمات الهامة في تخليق البروتين الحيوي،الحمض الريبي النووي النقال فئة عامة من الانز-تستخدم كمضات للعدوى. يشكل المخلق لأمينوأسيل
 عليه فقد تم ترخيص دواء واحد فقط يسمى ميبروسين كمثبط لهذا الانزيم. و نظرا لأن كل حمض أميني يتطلب مخلق الأمينوأسيل الحمض الريبي
مثبطات صميم و تشييد مركبات كيميائية تعمل كالنووى النقال فإنه يعتبر ثروة مناسبة لتصميم الأدوية الموجه. و بناًء عليه فإن البحث يتضمن ت
مقاومة لعديد من الأدوية ال ستافيلوكوكس أوريسلوظائف مخلق الفينيل ألانين الحمض الريبي النووي النقال و ذلك لعلاج العدوى التى تسببها بكتيريا 
باستخدام  ستافيلوكوكس أوريسبي النووي النقال لبكتيريا وذلك اعتمادا على نموذج التماثل الذى تم تصميمه لمخلق الفينيل ألانين الحمض الري
مخلق الفينيل ألانين الحمض الريبي النووي النقال لبكتيريا  بالاضافة الى دراسة تأثير هذه المركبات على انزيم برمجيات النمذجة الحاسوبية.
 ستريبتوكوكس نيمونيا و سيدومونس اريجينوزا.
 
